APICA: Difference between revisions

Line 1:

'''APICA''' (also known as '''SDB-001''', and '''2NE1''') is a novel synthetic [[psychoactive class::cannabinoid]] that produces modified [[cannabis|cannabis-like]] effects when [[routes of administration|administered]]. It has been shown to act as a potent [[agonist]] for the CB1 and CB2 [[cannabinoid]] [[receptors]].<ref>Samuel D. Banister, Jordyn Stuart, Richard C. Kevin, Amelia Edington, Mitchell Longworth, Shane M. Wilkinson, Corinne Beinat, Alexandra S. Buchanan, David E. Hibbs, Michelle Glass, Mark Connor, Iain S. McGregor, and Michael Kassiou. "Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135" Chemical Neuroscience. 2015;6(8);1445-1458;doi:10.1021/acschemneuro.5b00107 (Pubmed / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/25921407</ref>

Revision as of 22:45, 6 June 2017 view source >Unity m SubstanceBox rename. ← Older edit		Revision as of 02:52, 7 June 2017 view source >Kaylee m Undo revision 106598 - Changing the name to APICA with the justification that it is more commonly used is not corroborated by adequate research. Requires discussion. Newer edit →
Line 1:		Line 1:
	{{SubstanceBox/~~APICA~~}}		{{SubstanceBox/2NE1}}

	'''APICA''' (also known as '''SDB-001''', and '''2NE1''') is a novel synthetic [[psychoactive class::cannabinoid]] that produces modified [[cannabis\|cannabis-like]] effects when [[routes of administration\|administered]]. It has been shown to act as a potent [[agonist]] for the CB1 and CB2 [[cannabinoid]] [[receptors]].<ref>Samuel D. Banister, Jordyn Stuart, Richard C. Kevin, Amelia Edington, Mitchell Longworth, Shane M. Wilkinson, Corinne Beinat, Alexandra S. Buchanan, David E. Hibbs, Michelle Glass, Mark Connor, Iain S. McGregor, and Michael Kassiou. "Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135" Chemical Neuroscience. 2015;6(8);1445-1458;doi:10.1021/acschemneuro.5b00107 (Pubmed / NCBI) \| https://www.ncbi.nlm.nih.gov/pubmed/25921407</ref>		'''APICA''' (also known as '''SDB-001''', and '''2NE1''') is a novel synthetic [[psychoactive class::cannabinoid]] that produces modified [[cannabis\|cannabis-like]] effects when [[routes of administration\|administered]]. It has been shown to act as a potent [[agonist]] for the CB1 and CB2 [[cannabinoid]] [[receptors]].<ref>Samuel D. Banister, Jordyn Stuart, Richard C. Kevin, Amelia Edington, Mitchell Longworth, Shane M. Wilkinson, Corinne Beinat, Alexandra S. Buchanan, David E. Hibbs, Michelle Glass, Mark Connor, Iain S. McGregor, and Michael Kassiou. "Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135" Chemical Neuroscience. 2015;6(8);1445-1458;doi:10.1021/acschemneuro.5b00107 (Pubmed / NCBI) \| https://www.ncbi.nlm.nih.gov/pubmed/25921407</ref>